An observational study in Major Depressive Disorder, sponsored by Samsung Medical Center. Status unknown at 1 site in South Korea. Per ClinicalTrials.gov, last updated 2015-12-31.
Sponsored by Samsung Medical Center · Observational
The objective of this study is to investigate the antidepressant efficacy of rTMS, and to assess cortical metabolism before and after rTMS sessions in patients with major depression. We also aimed to investigate differences between the responders and nonresponders to rTMS and what would predict clinical response to rTMS.
The specific aims of this study is to: (1) evaluate the antidepressant efficacy of rTMS on major depression; (2) evaluate the effects of rTMS on cognitive function in depressive patients; (3) assess the effects of rTMS on cerebral glucose metabolism in depressive patients as measured by 18FDG PET; (4) investigate the differences of the regional cerebral glucose uptake changes during rTMS between responders and nonresponders to rTMS.
2,805 studies on the registry are indexed under Depressive Disorder, Major; 565 are open to participants now.
This study's planned enrollment of 40 is below the median of 135 across 365 observational studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →Samsung Medical Center is the lead sponsor of 1,005 studies on the registry; 148 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with major depressive disorder, who were not responsive to antidepressants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
repetitive Transcranial Magnetic Stimulation is a depressive patient group treated with rTMS
Device: repetitive Transcranial Magnetic Stimulation
10 times repetitive TMS, high frequency
Hamilton depression rating scale (HAM-D 17)
measuring instrument of severity of depressive symptoms
Time frame: baseline, 1, 2, and 4 weeks after TMS
This study is status unknown, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.